We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
+10.92%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$43.9B
AUM Growth
+$2.87B
(+7%)
Cap. Flow
-$890M
Cap. Flow
% of AUM
-2.03%
Top 10 Holdings %
Top 10 Hldgs %
13.25%
Holding
2,343
New
170
Increased
997
Reduced
1,015
Closed
150
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$111M |
| 2 |
Verizon
VZ
|
+$103M |
| 3 |
AT&T
T
|
+$103M |
| 4 |
Kroger
KR
|
+$97.1M |
| 5 |
3M
MMM
|
+$92.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$138M |
| 2 |
Tesla
TSLA
|
+$110M |
| 3 |
JPMorgan Chase
JPM
|
+$103M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$89.4M |
| 5 |
Apple
AAPL
|
+$85.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 16.25% |
| 3 | Financials | 11.85% |
| 4 | Industrials | 11.44% |
| 5 | Consumer Discretionary | 10.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1851
Holley
HLLY
$387M
| $446K | ﹤0.01% |
+210,203
| New | +$662K |
|
1852
Atara Biotherapeutics
ATRA
$80.3M
| $445K | ﹤0.01% |
5,428
-14,979
| -73% | -$1.56M |
|
1853
Green Brick Partners
GRBK
$3.08B
| $442K | ﹤0.01% |
18,246
+1,050
| +6% | +$24.3K |
|
1854
Vaalco Energy
EGY
$625M
| $442K | ﹤0.01% |
96,929
-171,989
| -64% | -$864K |
|
1855
Broadstone Net Lease
BNL
$3.97B
| $441K | ﹤0.01% |
27,213
-9,444
| -26% | -$158K |
|
1856
Pinterest
PINS
$13.4B
| $440K | ﹤0.01% |
18,613
-81,586
| -81% | -$1.95M |
|
1857
Energy Recovery
ERII
$396M
| $435K | ﹤0.01% |
21,214
+1,332
| +7% | +$29.1K |
|
1858
Agnico Eagle Mines
AEM
$91.9B
| $434K | ﹤0.01% |
8,354
-924
| -10% | -$43.6K |
|
1859
PubMatic
PUBM
$793M
| $433K | ﹤0.01% |
+33,812
| New | +$530K |
|
1860
OneWater Marine
ONEW
$217M
| $432K | ﹤0.01% |
15,091
+7,840
| +108% | +$245K |
|
1861
Gentherm
THRM
$1.28B
| $431K | ﹤0.01% |
6,605
-2,231
| -25% | -$144K |
|
|
HTO
1862
H2O America
HTO
$2.6B
| $431K | ﹤0.01% |
5,309
-12,234
| -70% | -$875K |
|
|
AIV
1863
Aimco
AIV
$382M
| $428K | ﹤0.01% |
60,159
+22,470
| +60% | +$171K |
|
1864
HighPeak Energy
HPK
$1.05B
| $427K | ﹤0.01% |
18,672
+288
| +2% | +$6.48K |
|
1865
V2X
VVX
$2.54B
| $425K | ﹤0.01% |
10,292
+70
| +0.7% | +$2.77K |
|
|
KDNY
1866
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $425K | ﹤0.01% |
16,207
+2,294
| +16% | +$50.8K |
|
1867
Worthington Enterprises
WOR
$2.8B
| $424K | ﹤0.01% |
13,974
-778
| -5% | -$24.1K |
|
1868
American Eagle Outfitters
AEO
$2.95B
| $423K | ﹤0.01% |
30,413
-737,941
| -96% | -$9.46M |
|
|
BPMC
1869
DELISTED
Blueprint Medicines
BPMC
| $422K | ﹤0.01% |
+9,628
| New | +$462K |
|
|
SOHU
1870
Sohu.com
SOHU
$373M
| $422K | ﹤0.01% |
30,751
| – | – |
|
1871
Array Technologies
ARRY
$821M
| $421K | ﹤0.01% |
21,756
-39,120
| -64% | -$743K |
|
|
AGEN
1872
Agenus
AGEN
$298M
| $420K | ﹤0.01% |
8,926
-24,550
| -73% | -$1.25M |
|
1873
Webster Financial
WBS
$12.8B
| $420K | ﹤0.01% |
8,910
-1,774
| -17% | -$88.8K |
|
1874
Huron Consulting
HURN
$2.46B
| $418K | ﹤0.01% |
5,763
+61
| +1% | +$4.49K |
|
1875
Digi International
DGII
$3.15B
| $418K | ﹤0.01% |
11,446
+824
| +8% | +$31.7K |
|
Similar funds
VGA
AQR Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, AQR Capital Management held 2,343 positions worth $43.9B, up 7% from $41B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
AQR Capital Management's Q4 2022 filing shows 170 new, 997 increased, 1,015 reduced and 150 closed positions. Its largest new stake was Generac Holdings: 310,080 shares worth $30.5M. The largest sale was Gilead Sciences, an estimated $138M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q4 2022 buy was Generac Holdings: 310,080 shares worth $30.5M.
- AQR Capital Management added most to Humana in Q4 2022, an estimated $111M increase.
- AQR Capital Management's biggest Q4 2022 reduction was Gilead Sciences, cutting an estimated $138M.
- AQR Capital Management fully exited Abiomed Inc in Q4 2022, selling an estimated $22.4M.
- AQR Capital Management's ten largest holdings make up 13% of its $43.9B portfolio in Q4 2022.
- AQR Capital Management opened 170 new positions and closed 150 in Q4 2022.
- AQR Capital Management's portfolio value rose 7% quarter-over-quarter to $43.9B.
Based on AQR Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.